Absci Reports Business Updates and First Quarter 2026 Financial and Operating Results

Successfully dosed all four planned healthy volunteer SAD cohorts of ongoing ABS-201™ HEADLINE trial; well-tolerated with favorable emerging safety data Preliminary pharmacokinetic (PK) modeling from HEADLINE trial supports ABS-201's targeted dosing interval Initiated dosing of first MAD cohort of